Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.50 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗

March 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

Via InvestorPlace

3 Up-and-Coming Growth Stocks to Buy Right Now ↗

March 25, 2023

These companies are small now but could grow much larger over time.

Via The Motley Fool

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

March 24, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

March 23, 2023

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know ↗

March 22, 2023

Via Benzinga

The Latest Analyst Ratings for Sarepta Therapeutics ↗

March 22, 2023

Via Benzinga

Sarepta Therapeutics' FDA Adcomm Puts Some Risk, With Potential Approval: Analyst ↗

March 17, 2023

Via Benzinga

Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process ↗

March 21, 2023

The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood...

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation

March 21, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Why did Sarepta Therapeutics Stock Plummet?

March 21, 2023

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

Via MarketBeat

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 17, 2023

Via Benzinga

Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy ↗

March 17, 2023

The decision is an about-face from what Sarepta said roughly two weeks ago.

Via Investor's Business Daily

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 17, 2023

Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp.

Via Benzinga

Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy ↗

March 17, 2023

Via Benzinga

First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday ↗

March 17, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Are Crypto Stocks COIN, MARA, RIOT, HUT, MSTR Up Today? ↗

March 17, 2023

Crypto stocks are on the rise Friday as traders celebrate another rally for Bitcoin (BTC) as it continues recent positive movement.

Via InvestorPlace

The 2 Stocks to Watch on a Nail-Biter Friday ↗

March 17, 2023

Investors are preparing for a volatile day.

Via The Motley Fool

NVDA Stock Price Prediction: Morgan Stanley Issues $304 Price Target for Nvidia Shares ↗

March 17, 2023

Nvidia (NVDA) stock is on the move Friday as investors react to a new price target from Morgan Stanley analyst Joseph Moore.

Via InvestorPlace

Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today? ↗

March 17, 2023

Sarepta Therapeutics (SRPT) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 17, 2023

The biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning!

Via InvestorPlace

Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket ↗

March 17, 2023

Gainers Enzo Biochem, Inc. (NYSE: ENZ) shares rose 89.9% to $2.26 in pre-market trading after the company announced it will sell its clinical laboratory to Labcorp.

Via Benzinga

Nasdaq, S&P Futures Dip, Signaling Pause In Rally As Focus Shifts To Next Week's Fed Decision: Analyst Says Brace For More Volatility Near Term ↗

March 17, 2023

The mood on Wall Street continues to be jittery, with the major index futures trading marginally to modestly lower. The weak sentiment reflected apprehensions concerning how the banking crisis will...

Via Benzinga

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

March 16, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 16, 2023

Via Benzinga

Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001

March 16, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

March 16, 2023

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Meta Platforms To Rally 27%? Here Are 10 Other Analyst Forecasts For Thursday ↗

March 09, 2023

Wells Fargo cut the price target for SVB Financial Group (NASDAQ: SIVB) from $350 to $300. Wells Fargo analyst Steven Shaw maintained an Overweight rating. SVB Financial shares fell 29.1% to $190.02 in...

Via Benzinga

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.